Genomic Determinants of Early Recurrences in Low-Stage, Low-Grade Endometrioid Endometrial Carcinoma. (14th June 2022)

• Record Type: Journal Article
• Authors: Safdar, Nida S; Stasenko, Marina; Selenica, Pier; Martin, Axel S; da Silva, Edaise M; Sebastiao, Ana Paula Martins; Krystel-Whittemore, Melissa; Abu-Rustum, Nadeem R; Reis-Filho, Jorge S; Soslow, Robert A; Shen, Ronglai; Mueller, Jennifer J; Oliva, Esther; Weigelt, Britta
• Is Part Of: Journal of the National Cancer Institute. Volume 114:Number 11(2022)
• Page Start: 1545
• Page End: 1548
• Publication Date: 2022-06-14
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djac119
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: Low-stage, low-grade endometrioid endometrial carcinoma (EEC), the most common histologic type of endometrial cancer, typically has a favorable prognosis. A subset of these cancers, however, displays an aggressive clinical course with early recurrences, including distant relapses. All statistical tests were 2-sided. Using a combination of whole-exome and targeted capture sequencing of 65 FIGO stage IA and IB grade 1 EECs treated with surgery alone, we demonstrate that chromosome 1q gain ( odds ratio [OR] = 8.09, 95% confidence interval [CI] = 1.59 to 54.6; P = .02), PIK3CA mutation (OR = 9.16, 95% CI = 1.95 to 61.8; P = .01), and DNA mismatch repair-deficient molecular subtype (OR = 7.92, 95% CI = 1.44 to 87.6; P = .02) are independent predictors of early recurrences within 3 years in this patient population. Chromosome 1q gain was validated in an independent dataset of stage I grade 1 EECs subjected to whole-exome sequencing. Our findings expand on the repertoire of genomic parameters that should be considered in the evaluation of patients with low-stage, low-grade EEC.